# Michael J Econs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7631431/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 67<br>papers | 8,545<br>citations | 126907<br>33<br>h-index | 114465<br>63<br>g-index |
| 70<br>all docs | 70<br>docs citations | 70<br>times ranked | 8213<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics, 2000, 26, 345-348. | 21.4 | 1,411 |
| 2 | Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia. New England Journal of Medicine, 2003, 348, 1656-1663. | 27.0 | 853 |
| 3 | Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity. American Journal of Surgical Pathology, 2004, 28, 1-30. | 3.7 | 587 |
| 4 | FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. Journal of Clinical Investigation, 2003, 112, 683-692. | 8.2 | 567 |
| 5 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97. | 27.8 | 548 |
| 6 | Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney International, 2001, 60, 2079-2086. | 5.2 | 443 |
| 7 | A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. Journal of Clinical Investigation, 2007, 117, 2684-2691. | 8.2 | 390 |
| 8 | Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nature Communications, 2018, 9, 260. | 12.8 | 295 |
| 9 | The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 497-500. | 3.6 | 292 |
| 10 | Autosomal Dominant Hypophosphatemic Rickets/Osteomalacia: Clinical Characterization of a Novel Renal Phosphate-Wasting Disorder. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 674-681. | 3.6 | 267 |
| 11 | Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3541-3549. | 3.6 | 250 |
| 12 | Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3111-3123. | 3.6 | 170 |
| 13 | Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. JAMA - Journal of the American Medical Association, 2020, 323, 432. | 7.4 | 162 |
| 14 | FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets. Journal of Bone and Mineral Research, 2007, 22, 520-526. | 2.8 | 149 |
| 15 | Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. Nature Communications, 2017, 8, 80. | 12.8 | 147 |
| 16 | Meta-Analysis of Genome-Wide Scans Provides Evidence for Sex- and Site-Specific Regulation of Bone Mass. Journal of Bone and Mineral Research, 2007, 22, 173-183. | 2.8 | 144 |
| 17 | Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1846-1850. | 3.6 | 138 |
| 18 | Ablation of the Galnt3 Gene Leads to Low-Circulating Intact Fibroblast Growth Factor 23 (Fgf23) Concentrations and Hyperphosphatemia Despite Increased Fgf23 Expression. Endocrinology, 2009, 150, 2543-2550. | 2.8 | 135 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Phenotypic Dissection of Bone Mineral Density Reveals Skeletal Site Specificity and Facilitates the Identification of Novel Loci in the Genetic Regulation of Bone Mass Attainment. PLoS Genetics, 2014, 10, e1004423. | 3.5 | 134 |
| 20 | Autosomal Dominant Osteopetrosis: Clinical Severity and Natural History of 94 Subjects with a Chloride Channel 7 Gene Mutation. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 771-778. | 3.6 | 129 |
| 21 | Genetics of Osteoporosis. , 2002, 23, 303-326. | | 115 |
| 22 | The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 497-500. | 3.6 | 111 |
| 23 | Genome Screen for Quantitative Trait Loci Underlying Normal Variation in Femoral Structure. Journal of Bone and Mineral Research, 2001, 16, 985-991. | 2.8 | 106 |
| 24 | Novel GALNT3 Mutations Causing Hyperostosis-Hyperphosphatemia Syndrome Result in Low Intact Fibroblast Growth Factor 23 Concentrations. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1943-1947. | 3.6 | 76 |
| 25 | Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. Journal of Bone and Mineral Research, 2016, 31, 1845-1854. | 2.8 | 67 |
| 26 | Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residues. European Journal of Human Genetics, 1999, 7, 615-619. | 2.8 | 60 |
| 27 | Osteopetroses, emphasizing potential approaches to treatment. Bone, 2017, 102, 50-59. | 2.9 | 53 |
| 28 | Sibling Pair Linkage and Association Studies between Bone Mineral Density and the Insulin-Like Growth Factor I Gene Locus1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4467-4471. | 3.6 | 52 |
| 29 | Confirmation of Linkage to Chromosome 1q for Peak Vertebral Bone Mineral Density in Premenopausal White Women. American Journal of Human Genetics, 2004, 74, 223-228. | 6.2 | 46 |
| 30 | Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice. Endocrinology, 2016, 157, 722-736. | 2.8 | 43 |
| 31 | Disentangling the genetics of lean mass. American Journal of Clinical Nutrition, 2019, 109, 276-287. | 4.7 | 38 |
| 32 | Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone, 2014, 59, 66-75. | 2.9 | 36 |
| 33 | Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone, 2016, 86, 98-105. | 2.9 | 36 |
| 34 | Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Reports, 2018, 2018, bcr-2017-222851. | 0.5 | 36 |
| 35 | A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells. Journal of Bone and Mineral Research, 2012, 27, 453-460. | 2.8 | 34 |
| 36 | Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Ironâ€Ðeficient Patients With Autosomal Dominant Hypophosphatemic Rickets. Journal of Bone and Mineral Research, 2020, 35, 231-238. | 2.8 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone, 2014, 60, 87-92. | 2.9 | 29 |
| 38 | Meta-Analysis of Genomewide Association Studies Reveals Genetic Variants for Hip Bone Geometry. Journal of Bone and Mineral Research, 2019, 34, 1284-1296. | 2.8 | 27 |
| 39 | Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. Journal of Clinical Investigation, 2018, 128, 5368-5373. | 8.2 | 27 |
| 40 | Chromosomal localization of two human genes involved in phosphate homeostasis: the type IIb sodium-phosphate cotransporter and stanniocalcin-2. Somatic Cell and Molecular Genetics, 1998, 24, 357-362. | 0.7 | 25 |
| 41 | Interferon Gamma, but not Calcitriol Improves the Osteopetrotic Phenotypes in ADO2 Mice. Journal of Bone and Mineral Research, 2015, 30, 2005-2013. | 2.8 | 24 |
| 42 | A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice. Endocrinology, 2017, 158, 470-476. | 2.8 | 21 |
| 43 | Novel PHEX gene locusâ€specific database: Comprehensive characterization of vast number of variants associated with Xâ€linked hypophosphatemia (XLH). Human Mutation, 2022, 43, 143-157. | 2.5 | 18 |
| 44 | Hypophosphatemic rickets. , 2001, 2, 165-173. | | 17 |
| 45 | Dosage Effect of a Phex Mutation in a Murine Model of X-Linked Hypophosphatemia. Calcified Tissue International, 2013, 93, 155-162. | 3.1 | 17 |
| 46 | Conventional Therapy in Adults With XLH Improves Dental Manifestations, But Not Enthesopathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3622-3624. | 3.6 | 16 |
| 47 | Bone Mass and Strength are Significantly Improved in Mice Overexpressing Human WNT16 in Osteocytes. Calcified Tissue International, 2017, 100, 361-373. | 3.1 | 16 |
| 48 | Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis. Journal of Bone and Mineral Research, 2019, 34, 1436-1445. | 2.8 | 16 |
| 49 | Osteopathia Striata with Cranial Sclerosis. Journal of Bone and Mineral Research, 1999, 14, 152-153. | 2.8 | 14 |
| 50 | Polymorphisms in the bone morphogenetic protein 2 (BMP2) gene do not affect bone mineral density in white men or women. Osteoporosis International, 2006, 17, 587-592. | 3.1 | 13 |
| 51 | Intronic deletions in the SLC34A3 gene: A cautionary tale for mutation analysis of hereditary hypophosphatemic rickets with hypercalciuria. Bone, 2014, 59, 53-56. | 2.9 | 13 |
| 52 | Fine mapping of bone structure and strength QTLs in heterogeneous stock rat. Bone, 2015, 81, 417-426. | 2.9 | 11 |
| 53 | Phenotypic severity of autosomal dominant osteopetrosis type II (ADO2) mice on different genetic backgrounds recapitulates the features of human disease. Bone, 2017, 94, 34-41. | 2.9 | 11 |
| 54 | SIBLING family genes and bone mineral density: Association and allele-specific expression in humans. Bone, 2014, 64, 166-172. | 2.9 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Genetic diseases resulting from disordered FGF23/klotho biology. Bone, 2017, 100, 56-61. | 2.9 | 10 |
| 56 | Sibling Pair Linkage and Association Studies between Peak Bone Mineral Density and the Gene Locus for the Osteoclast-Specific Subunit (OC116) of the Vacuolar Proton Pump on Chromosome 11p12-13. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3819-3824. | 3.6 | 10 |
| 57 | Bone mineral density and laboratory evaluation of a type II autosomal dominant osteopetrosis carrier. , 1999, 85, 9-12. | | 7 |
| 58 | Chapter 23. Fibroblast Growth Factor-23. , 0, , 112-116. | | 6 |
| 59 | Radiographic imaging, densitometry and disease severity in Autosomal dominant osteopetrosis type 2. Skeletal Radiology, 2021, 50, 903-913. | 2.0 | 6 |
| 60 | CLCN7 polymorphisms and bone mineral density in healthy premenopausal white women and in white men. Bone, 2008, 43, 995-998. | 2.9 | 5 |
| 61 | Localization of PiUS, a stimulator of cellular phosphate uptake to human chromosome 3p21.3. Somatic Cell and Molecular Genetics, 1998, 24, 71-74. | 0.7 | 3 |
| 62 | Genome-wide association study of serum iron phenotypes in premenopausal women of European descent. Blood Cells, Molecules, and Diseases, 2016, 57, 50-53. | 1.4 | 3 |
| 63 | The Case \| Ectopic calcifications in a child. Kidney International, 2015, 87, 1079-1081. | 5.2 | 2 |
| 64 | OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials. Journal of the Endocrine Society, 2019, 3, . | 0.2 | 2 |
| 65 | Case 18-2022: A 29-Year-Old Woman with Recurrent Fractures. New England Journal of Medicine, 2022, 386, 2316-2326. | 27.0 | 2 |
| 66 | Chloroquine increases osteoclast activity in vitro but does not improve the osteopetrotic bone phenotype of ADO2 mice. Bone, 2021, 153, 116160. | 2.9 | 1 |
| 67 | Unusual Cortical Phenotype After Hematopoietic Stem Cell Transplantation in a Patient With Osteopetrosis. JBMR Plus, 2022, 6, . | 2.7 | 1 |